Azd6489

Preclinical

AstraZeneca

Azd6489 is one of 7 therapeutic programs targeting Respiratory Syncytial Virus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Respiratory Syncytial VirusActive, not recruiting

Respiratory Syncytial VirusPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Respiratory Syncytial Virus

#DrugCompanyPhaseTrials

Mrna-1345

Moderna

Phase 3

4 2

RSV Vaccine 1

Sanofi

Phase 2

4 3

ABO1105

SSuzhou Abogen Biosciences Co., Ltd.

Phase 2

2 4

Mrna-1365

Moderna

Phase 1

1 5

Bivalent RSV Vaccine (IN006)

SShenzhen Shenxin Biotechnology Co., Ltd

Phase 1

2 6

Control Vaccine

GSK

Preclinical

1 7

Azd6489

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Respiratory Syncytial Virus

NCT07717840

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

A Phase I/II, Randomized, Double-Blind, Active-Controlled Study to Characterize the Safety and Immunogenicity of AZD6489 in Adults 60 Years of Age and Older

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07717840·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azd6489. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Azd6489. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AstraZeneca

Azd6489

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

References

Drug Info

Quick Facts

Related News